Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

• Published in: The Journal of pathology Vol. 200; no. 3; pp. 290 - 297
• Main Authors: Witton, Caroline J, Reeves, Jonathan R, Going, James J, Cooke, Timothy G, Bartlett, John MS
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.07.2003
• Subjects: breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - mortality; c-erbB2; EGFR; Female; Gene Expression Regulation, Neoplastic - genetics; Genes, erbB - genetics; Genes, erbB-1 - genetics; Genes, erbB-2; HER receptors; HER2/neu; Humans; Immunohistochemistry - methods; Prognosis; Protein-Tyrosine Kinases - genetics; Receptor, Epidermal Growth Factor - genetics; Receptor, ErbB-2 - genetics; Receptor, ErbB-3 - genetics; Receptor, ErbB-4; Receptors, Estrogen - analysis
• ISSN: 0022-3417; 1096-9896
• DOI: 10.1002/path.1370

EGFr/HER1 and c‐erbB‐2/HER2 expression are associated with poor prognosis in breast cancer. The type I receptor tyrosine kinase (RTK) family to which they belong has four members (HER1–4). In this study, expression of HER1–4 and oestrogen receptor (ER) expression were determined by immunohistochemistry in 220 breast carcinomas. Elevated expression of HER1 was observed in 16.4%, HER2 in 22.8%, HER3 in 17.5%, and HER4 in 11.9% of these tumours. Patients whose tumours overexpressed HER1, 2 or 3 had reduced survival (p = <0.001), whereas those whose tumours overexpressed HER4 had increased survival (p = 0.013); 38.6% of cases overexpressed one or more of HER1, 2 or 3. HER4 was rarely overexpressed with other HERs (1.4% of cases). Cox's multiple regression analysis demonstrated that overexpression of HER1/2/3, HER4, and standard prognostic indicators independently affected survival. HER1–3 expression was related to ER negativity (p < 0.0001, χ2). Patients with ER‐positive, HER1–3‐positive tumours had a significantly poorer survival (p < 0.001) than those with ER‐positive/HER‐negative or HER4‐positive tumours. Expression of HER RTKs displays complex interactions between different family members. There is a strong interaction, in terms of survival, between HER expression and ER expression. The development of HER‐targeted agents (eg Herceptin, Iressa), and agents targeted at the downstream signalling pathways, therefore provides new possibilities in the treatment of breast cancer. Copyright © 2003 John Wiley & Sons, Ltd.